Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
AuthorsPeng S, Adelman RA, Rizzolo LJ,
JournalInvest Ophthalmol Vis Sci
PubMed ID20042644
Bevacizumab and ranibizumab are currently used to treat age-related macular degeneration by neutralizing vascular endothelial growth factor (VEGF). In this study, the potential side effects on the outer blood-retinal barrier were examined. Human fetal RPE (hfRPE) cells were used because they are highly differentiated in culture. The claudin composition of ... More